US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Decoy Therapeutics Inc

1.72

-0.1400-7.55%

Volume:241.76K

Turnover:410.41K

Market Cap:1.12M

PE:-0.04

High:1.88

Open:1.88

Low:1.61

Close:1.86

52wk High:55.92

52wk Low:1.61

Shares:655.19K

Float Shares:586.42K

Volume Ratio:0.58

T/O Rate:41.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-40.3963

EPS(LYR):-129.1004

ROE:-827.77%

ROA:-73.35%

PB:0.26

PE(LYR):-0.01

Loading ...

Overview Company News Filings

Decoy Therapeutics Adds Moderna Executive Patricia Gauthier to Board

Press Release: Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors

Decoy Therapeutics Files to Register Up to 3.77 Million Shares for Resale

MT Newswires Live

Top Premarket Decliners

MT Newswires Live

Why Is Penny Stock Decoy Therapeutics (DCOY) Up Today?

NASDAQ Trade Halt Volatility Trading Pause at 09:37 Am

Decoy Therapeutics Inc trading halted, volatility trading pause

Top Premarket Gainers

MT Newswires Live

Decoy Therapeutics Enters $3.5 Million PIPE Priced at USD 5.91 Per Share

Press Release: Decoy Therapeutics, Inc. Announces up to $21 Million Private Placement Financing

Decoy Therapeutics posts investor presentation on D-MAV multi-viral fusion inhibitor platform

Decoy Therapeutics Inc trading halted, volatility trading pause

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:42 AM

Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors

THOMSON REUTERS

Decoy Therapeutics partners with hVIVO to advance D-MAV antivirals into Phase 1, Phase 2a studies

Decoy Therapeutics names MIT professor Brad Pentelute chair of scientific advisory board

Decoy Therapeutics Names Brad Pentelute, Mit Professor of Chemistry, as Chair of Scientific Advisory Board

THOMSON REUTERS

Press Release: Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board

Decoy Therapeutics announces 2026 annual shareholder meeting

Decoy Therapeutics Q1 net loss widens to $2.22 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/DCOY/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"DCOY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","market":"US","secType":"STK","nameCN":"Decoy Therapeutics Inc","latestPrice":1.715,"timestamp":1790970860250,"preClose":1.855,"halted":0,"volume":241763,"delay":0,"changeRate":-0.07547169811320749,"floatShares":586415,"shares":655185,"eps":-40.396286,"marketStatus":"Trading","change":-0.14,"latestTime":"10-02 15:54:48 EDT","open":1.88,"high":1.88,"low":1.61,"amount":410409.2049129,"amplitude":0.145553,"askPrice":1.73,"askSize":300,"bidPrice":1.7,"bidSize":444,"shortable":0,"etf":0,"ttmEps":-40.396286,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1790971200000},"marketStatusCode":2,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":1.855,"preHourTrading":{"tag":"盘前","latestPrice":1.82,"preClose":1.855,"latestTime":"09:29 EDT","volume":15316,"amount":27243.350316,"timestamp":1790947761102,"change":-0.035,"changeRate":-0.018868,"amplitude":0.080863},"postHourTrading":{"tag":"盘后","latestPrice":1.8532,"preClose":1.855,"latestTime":"19:59 EDT","volume":4554,"amount":8477.2047,"timestamp":1790899155013,"change":-0.0018,"changeRate":-0.00097,"amplitude":0.021563},"volumeRatio":0.579981},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","floatShares":586415,"roa":"-73.35%","roe":"-827.77%","lyrEps":-129.100415,"volumeRatio":0.579981,"shares":655185,"dividePrice":0,"high":1.88,"amplitude":0.145553,"preClose":1.855,"low":1.61,"week52Low":1.61,"pbRate":"0.26","psRate":"4.94","week52High":55.92,"institutionHeld":0,"latestPrice":1.715,"committee":0.193548,"eps":-40.396286,"divideRate":0,"volume":241763,"delay":0,"ttmEps":-40.396286,"open":1.88,"prevYearClose":7.7856,"prevWeekClose":3.09,"prevMonthClose":1.97,"prevQuarterClose":1.97,"fiveDayClose":3.09,"twentyDayClose":2.88,"sixtyDayClose":6.265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DCOY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"DCOY","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-4.46},{"market":"US","date":"2026-05-08","symbol":"DCOY","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"post","actualEps":-4.18},{"market":"US","date":"2026-03-31","symbol":"DCOY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2026-03-09","symbol":"DCOY","defaultRemindTime":1773063000000,"type":"split","dateTimestamp":1773028800000,"forFactor":12,"toFactor":1,"ratio":12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DCOY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DCOY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DCOY","date":"2026-10-01","current":-0.042454,"percent":1,"low":-1.594527,"twenty":-0.855941,"median":-0.249381,"eighty":-0.158771,"high":-0.089326,"avg":-0.438309,"sd":0.345507,"marketCap":1290714},"quantilePoints":[{"date":"2026-01-09","current":-0.982229,"twenty":-1.053663,"median":-1.026876,"eighty":-1.000088,"marketCap":4915816},{"date":"2026-01-16","current":-1.227403,"twenty":-1.203881,"median":-1.071522,"eighty":-1.040856,"marketCap":6142855},{"date":"2026-01-23","current":-0.957354,"twenty":-1.160688,"median":-1.045754,"eighty":-0.982229,"marketCap":4791324},{"date":"2026-01-30","current":-1.05749,"twenty":-1.109791,"median":-1.050666,"eighty":-0.994985,"marketCap":5292482},{"date":"2026-02-06","current":-0.790885,"twenty":-1.101882,"median":-1.039631,"eighty":-0.91832,"marketCap":3958189},{"date":"2026-02-13","current":-0.956844,"twenty":-1.071522,"median":-0.994921,"eighty":-0.926101,"marketCap":4788771},{"date":"2026-02-20","current":-1.018456,"twenty":-1.060296,"median":-0.989117,"eighty":-0.939163,"marketCap":5097126},{"date":"2026-02-27","current":-0.871249,"twenty":-1.05596,"median":-0.982229,"eighty":-0.908242,"marketCap":4360392},{"date":"2026-03-06","current":-0.74305,"twenty":-1.047719,"median":-0.957099,"eighty":-0.869974,"marketCap":3718783},{"date":"2026-03-13","current":-0.796199,"twenty":-1.041162,"median":-0.954292,"eighty":-0.863596,"marketCap":3984784},{"date":"2026-03-20","current":-0.84935,"twenty":-1.039708,"median":-0.934265,"eighty":-0.844716,"marketCap":4250791},{"date":"2026-03-27","current":-0.746769,"twenty":-1.027385,"median":-0.915268,"eighty":-0.830428,"marketCap":3737398},{"date":"2026-04-02","current":-0.671826,"twenty":-1.020803,"median":-0.90314,"eighty":-0.800664,"marketCap":3362328},{"date":"2026-04-10","current":-0.254968,"twenty":-1.004373,"median":-0.87465,"eighty":-0.787058,"marketCap":3191808},{"date":"2026-04-17","current":-0.249443,"twenty":-0.994908,"median":-0.869974,"eighty":-0.73327,"marketCap":3122652},{"date":"2026-04-24","current":-0.230321,"twenty":-0.987969,"median":-0.855197,"eighty":-0.507377,"marketCap":2883266},{"date":"2026-05-01","current":-0.257092,"twenty":-0.982688,"median":-0.845098,"eighty":-0.256242,"marketCap":3218406},{"date":"2026-05-08","current":-0.243919,"twenty":-0.982229,"median":-0.84006,"eighty":-0.250421,"marketCap":3053496},{"date":"2026-05-15","current":-0.184485,"twenty":-0.974422,"median":-0.810018,"eighty":-0.248296,"marketCap":2404495},{"date":"2026-05-22","current":-0.262442,"twenty":-0.962099,"median":-0.79992,"eighty":-0.247659,"marketCap":3420554},{"date":"2026-05-29","current":-0.322848,"twenty":-0.95715,"median":-0.794073,"eighty":-0.248169,"marketCap":4207866},{"date":"2026-06-05","current":-0.27387,"twenty":-0.956742,"median":-0.781317,"eighty":-0.248169,"marketCap":3569505},{"date":"2026-06-12","current":-0.24081,"twenty":-0.95567,"median":-0.74491,"eighty":-0.247404,"marketCap":3138611},{"date":"2026-06-18","current":-0.24285,"twenty":-0.952787,"median":-0.706406,"eighty":-0.245537,"marketCap":3165209},{"date":"2026-06-26","current":-0.241544,"twenty":-0.945899,"median":-0.6697,"eighty":-0.244973,"marketCap":3148186},{"date":"2026-07-02","current":-0.311012,"twenty":-0.942429,"median":-0.364072,"eighty":-0.244891,"marketCap":4053596},{"date":"2026-07-10","current":-0.255707,"twenty":-0.926101,"median":-0.334889,"eighty":-0.244891,"marketCap":3332779},{"date":"2026-07-17","current":-0.244483,"twenty":-0.91832,"median":-0.322848,"eighty":-0.24285,"marketCap":3186488},{"date":"2026-07-24","current":-0.201627,"twenty":-0.915268,"median":-0.304685,"eighty":-0.239993,"marketCap":2627921},{"date":"2026-07-31","current":-0.159996,"twenty":-0.910668,"median":-0.29693,"eighty":-0.235273,"marketCap":2085314},{"date":"2026-08-07","current":-0.16571,"twenty":-0.904416,"median":-0.286523,"eighty":-0.233302,"marketCap":2159790},{"date":"2026-08-14","current":-0.129959,"twenty":-0.896201,"median":-0.26684,"eighty":-0.229711,"marketCap":1877847},{"date":"2026-08-21","current":-0.148725,"twenty":-0.881334,"median":-0.262442,"eighty":-0.225153,"marketCap":2149006},{"date":"2026-08-28","current":-0.134668,"twenty":-0.872609,"median":-0.257114,"eighty":-0.215096,"marketCap":1945899},{"date":"2026-09-04","current":-0.130588,"twenty":-0.870229,"median":-0.255393,"eighty":-0.199995,"marketCap":1886932},{"date":"2026-09-11","current":-0.123786,"twenty":-0.869974,"median":-0.254968,"eighty":-0.182689,"marketCap":1788655},{"date":"2026-09-18","current":-0.12832,"twenty":-0.869208,"median":-0.250612,"eighty":-0.16971,"marketCap":1854173},{"date":"2026-09-25","current":-0.141017,"twenty":-0.862829,"median":-0.250293,"eighty":-0.16473,"marketCap":2037625},{"date":"2026-10-01","current":-0.089326,"twenty":-0.855941,"median":-0.249381,"eighty":-0.158771,"marketCap":1290714}],"updateTime":1790970888813},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DCOY\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651466644","title":"Decoy Therapeutics Adds Moderna Executive Patricia Gauthier to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2651466644","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651466644?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:25","pubTimestamp":1784121940,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics adds Moderna executive Patricia Gauthier to boardDecoy Therapeutics stockholders elected Patricia Gauthier as a Class II director at the July 14, 2026 annual meeting.Gauthier has be","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDLc52tY0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","MRNX","BK4139","BK4585","BK4501","DCOY","LGHT","MRNY","BK4588","WDNA","BK4548","BK4568","BK4534","BK4533","GNOM","MRNA","BK4551","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651466612","title":"Press Release: Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651466612","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651466612?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:25","pubTimestamp":1784121900,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs(TM)), a new category of antivirals engine","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4588","BK4539","LENZ","BK4007","03160","DCOY","BK4585","BK4139","BK4604","TM","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650493137","title":"Decoy Therapeutics Files to Register Up to 3.77 Million Shares for Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2650493137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650493137?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:45","pubTimestamp":1783716321,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics  on Friday filed a statement to register the resale of up to 3.77 million shares of common stock issuable upon the exercise of warrants issued in a private placement that closed on June 29.The company said it is not selling any shares under the registration statement and will not receive proceeds from sales by the selling stockholders, though it may receive proceeds from any cash exercise of the warrants.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","LENZ","BK4007","DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647755810","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647755810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647755810?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:35","pubTimestamp":1782819325,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics  shares were down 37% in Tuesday premarket activity, following the previous session's 8% gain.GMEX Robotics  stock was down 34% after the company said it would implement a 1-for-9 share consolidation of its Class A and Class B ordinary shares.Universe Pharmaceuticals  shares were down 29% after the previous session's 311% rally.Nuvectis Pharma  stock was down 24% after the company priced a secondary offering of 5 million common shares at $20 per share.Decoy Therapeutics  shares were down 21%, following the earlier session's 74% gain.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["UNCY","DCOY","NVCT","BK4007","BK4139","BK4539","GMEX","BK4200","UPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647130969","title":"Why Is Penny Stock Decoy Therapeutics (DCOY) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2647130969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647130969?lang=en_us&edition=fundamental","pubTime":"2026-06-30 01:47","pubTimestamp":1782755240,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics stock rallied on Monday alongside news of new funding for the company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-penny-stock-decoy-therapeutics-dcoy-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-penny-stock-decoy-therapeutics-dcoy-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372495","title":"NASDAQ Trade Halt Volatility Trading Pause at 09:37 Am","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372495","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372495?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:37","pubTimestamp":1782740239,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 09:37 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nAQN2M63PJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372737","title":"Decoy Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372737?lang=en_us&edition=fundamental","pubTime":"2026-06-29 21:35","pubTimestamp":1782740122,"startTime":"0","endTime":"0","summary":"09:31 EDT Decoy Therapeutics (DCOY) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-inc-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-inc-trading-halted-volatility-trading-pause-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647224375","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2647224375","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647224375?lang=en_us&edition=fundamental","pubTime":"2026-06-29 19:05","pubTimestamp":1782731124,"startTime":"0","endTime":"0","summary":"Universe Pharmaceuticals  shares were up 170% in Monday premarket activity after the company said late Friday it agreed to acquire Best Praise International for about $10.8 million.Decoy Therapeutics  stock was 146% higher after the company agreed to a private placement of about $3.5 million with a single healthcare-focused institutional investor.Sagtec Global  shares were up 26%, recovering from a 27% decline in Friday's session.Comcast  stock was 22% higher after the company said it plans to separate into two publicly traded companies through a tax-free spin-off of its NBCUniversal and Sky businesses.Palatin Technologies  shares were up 22%, adding to a 9% gain in the previous session.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765489.SGD","BK4598","BK4100","LU1059921491.USD","LU1244550221.USD","LU0980610538.SGD","PTN.AU","IE00BSNM7G36.USD","LU1244550494.USD","CMCSA","LU1894683348.USD","LU1201861249.SGD","PTN","BK4566","LU0868494617.USD","LU0942090050.USD","LU1244550577.SGD","BK4115","UPC","LU1150488135.SGD","BK4550","BK4585","LU1150488218.USD","BK4534","LU0868494708.USD","LU0708994859.HKD","IE00B894F039.SGD","LU0070302665.USD","BK4588","BK4581","BK4023","LU1489326972.SGD","SAGT","LU0878866978.SGD","LU0068578508.USD","LU0985489474.SGD","LU1267930573.SGD","BK4139","BK4007","LU0029864427.USD","BK7095","DCOY","LU0433182093.SGD","BK4507","IE00B19Z9Z06.USD","LU0128525929.USD","LU0648001328.SGD","LU0208291251.USD","LU1074936037.SGD","LU0310800379.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646267395","title":"Decoy Therapeutics Enters $3.5 Million PIPE Priced at USD 5.91 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2646267395","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646267395?lang=en_us&edition=fundamental","pubTime":"2026-06-27 08:12","pubTimestamp":1782519137,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics enters $3.5 million PIPE priced at USD 5.91 per shareDecoy Therapeutics entered a PIPE with one healthcare-focused institutional investor for USD 3.5 million in upfront gross procee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260627:nNDL8nzTY3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646395269","title":"Press Release: Decoy Therapeutics, Inc. Announces up to $21 Million Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2646395269","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646395269?lang=en_us&edition=fundamental","pubTime":"2026-06-27 08:12","pubTimestamp":1782519120,"startTime":"0","endTime":"0","summary":"HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the \"Company\" or \"Decoy\"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs(TM)), a new category o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TM","BK4539","BK4585","03160","BK4604","BK4099","BK4007","BK4139","DCOY","BK4588","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645043589","title":"Decoy Therapeutics posts investor presentation on D-MAV multi-viral fusion inhibitor platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2645043589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645043589?lang=en_us&edition=fundamental","pubTime":"2026-06-22 12:03","pubTimestamp":1782101006,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics highlighted its Designable Multi-Antivirals platform targeting viral fusion inhibition, aiming for one drug to cover multiple viruses.Presentation cited a structurally conserved target across 250+ human-infecting viruses, with programs designed to address 70%+ of annual virus-positive respiratory infections.Non-dilutive funding totaled $6.5 million, positioned as support from global health, technology, and government organizations.Company pointed to $5.7 billion in 2024 Paxlovid sales as evidence of a large, persistent antiviral market driven by mutation risk.Development plan emphasized two clinical programs in 24 months, enabled by an AI/ML design-build-test-learn workflow on Google Cloud.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6wXmd0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642633499","title":"Decoy Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2642633499","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642633499?lang=en_us&edition=fundamental","pubTime":"2026-06-09 23:45","pubTimestamp":1781019930,"startTime":"0","endTime":"0","summary":"11:42 EDT Decoy Therapeutics (DCOY) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-inc-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/decoy-therapeutics-inc-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642549605","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:42 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2642549605","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642549605?lang=en_us&edition=fundamental","pubTime":"2026-06-09 23:42","pubTimestamp":1781019725,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:42 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nAQN2M2RKM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640901585","title":"Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640901585","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640901585?lang=en_us&edition=fundamental","pubTime":"2026-06-03 20:00","pubTimestamp":1780488029,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA5Q3C6H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640955206","title":"Decoy Therapeutics partners with hVIVO to advance D-MAV antivirals into Phase 1, Phase 2a studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2640955206","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640955206?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:06","pubTimestamp":1780311998,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics signed a strategic development initiative with clinical partner hVIVO to move its lead D-MAV antiviral into Phase 1 and Phase 2a studies.hVIVO will support trial planning, regulatory strategy, translational modeling, and preparation of European and UK clinical trial submissions, including EMA and MHRA interactions.The work is intended to create a reusable development template across Decoy’s D-MAV portfolio, subject to regulatory feedback.Decoy plans to pursue early proof-of-concept studies with hVIVO, while also targeting US registration with the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief on June 01, 2026, and is solely r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL3qzrCx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514437","title":"Decoy Therapeutics names MIT professor Brad Pentelute chair of scientific advisory board","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514437","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514437?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:15","pubTimestamp":1779797739,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics named Brad L. Pentelute as chair of its scientific advisory board on May 26, 2026.Pentelute is a co-founder of Decoy. He has served as a technology adviser since inception.He is a professor of chemistry at MIT. His work focuses on peptide synthesis, protein engineering, rapid flow synthesis.He succeeds Shahin Gharakhanian as SAB chair. Gharakhanian will continue working with the company.Pentelute will help guide the IMP3ACT platform, supporting development of designable multi-antivirals toward clinical-stage progress.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL3gvQgJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514924","title":"Decoy Therapeutics Names Brad Pentelute, Mit Professor of Chemistry, as Chair of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514924","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514924?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:15","pubTimestamp":1779797700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUA4TRHDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638514148","title":"Press Release: Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2638514148","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638514148?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:15","pubTimestamp":1779797700,"startTime":"0","endTime":"0","summary":"Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development. As Chair of the SAB, Dr. Pentelute will help guide the scientific direction of Decoy's IMP ACT platform and its expanding pipeline of Designable Multi-Antivirals , a new category of antivirals engineered to target shared viral mechanisms, enabling a single drug to work across multiple viral threats. IMP ACT, Decoy's proprietary peptide conjugate platform, integrates AI-enabled design with rapid synthesis to advance candidates faster than traditional approaches.Dr. Pentelute is a leader in the chemistry of peptides and proteins, with research that spans rapid flow peptide synthesis, intracellular delivery, and the discovery of selective binders for therapeutic targets. His laboratory at MIT has pioneered automated technologies that dramatically compress the time required to design, build, and test new peptide therapeutics, an approach central to the IMP ACT pl","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK6515","BK4585","BK4588","MIT","BK6062","BK4555","BK4099","LENZ","TM","BK4007","BK4139","M11.SI","BK4604","03160","DCOY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636861041","title":"Decoy Therapeutics announces 2026 annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2636861041","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636861041?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:09","pubTimestamp":1779221373,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics will hold its 2026 annual meeting of stockholders in Houston on July 14, 2026.Stockholders on record as of May 22, 2026 will be eligible to vote at the meeting.The company set May 29, 2026 as the deadline for shareholder proposals intended for inclusion in the proxy materials.May 29, 2026 is also the cutoff for advance notices to nominate director candidates or submit other business for consideration at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 19, 2026, and is solely responsib","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL8VhtJy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DCOY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634462202","title":"Decoy Therapeutics Q1 net loss widens to $2.22 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634462202","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634462202?lang=en_us&edition=fundamental","pubTime":"2026-05-09 04:46","pubTimestamp":1778273200,"startTime":"0","endTime":"0","summary":"Decoy Therapeutics posted a net loss of USD 2.22 million, widening from USD 1.71 million a year earlier.Research and development expenses more than doubled to 749,813, driven mainly by the November 2025 merger and addition of the IMP3ACT  program.General and administrative costs edged down to USD 1.53 million from USD 1.64 million, while interest income and other rose to 59,111 from 9,162.Cash, cash equivalents and restricted cash totaled USD 7.8 million, including about USD 3 million restricted under the Gates Foundation grant, with funding expected to last into late 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Decoy Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Dat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL7wLWQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DCOY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":44,"code":"91000000","status":"200"}]}}